1. PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. (August 2018) Authors: Dillon, M.T.; Boylan, Z.; Smith, D.; Guevara, J.; Mohammed, K.; Peckitt, C.; Saunders, M.; Banerji, U.; Clack, G.; Smith, S.A.; Spicer, J.F.; Forster, M.D.; Harrington, K.J. Journal: Clinical and translational radiation oncology Issue: Volume 12(2018) Page Start: 16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗